Global Growth Companies With High Insider Ownership For September 2026

In September 2026, global markets are navigating a complex landscape marked by inflationary pressures and geopolitical tensions, particularly in the Middle East, which have driven oil prices higher and influenced investor sentiment. As major indices like the Russell 2000 and S&P MidCap 400 experience declines, investors are increasingly looking towards growth companies with high insider ownership as potential opportunities amidst these uncertainties. In this environment, stocks with substantial insider ownership can be appealing due to the alignment of interests between company management and shareholders.

Top 10 Growth Companies With High Insider Ownership Globally

Name	Insider Ownership	Earnings Growth
Zhejiang Taotao Vehicles (SZSE:301345)	27.9%	31.7%
Suzhou Dongshan Precision Manufacturing (SZSE:002384)	33.5%	75.5%
Shanghai Biren Technology (SEHK:6082)	10.4%	126%
Meitu (SEHK:1357)	22.9%	30.7%
Jiangxi Fushine Pharmaceutical (SZSE:300497)	21.1%	50.8%
Guangdong Shenling Environmental Systems (SZSE:301018)	36.7%	65.4%
Gpixel Changchun Microelectronics (SEHK:3277)	18.2%	31.9%
Fulin Precision (SZSE:300432)	11.2%	66.5%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	14.1%	39.2%
Beijing Luzhu Biotechnology (SEHK:2480)	39.7%	84.3%

Click here to see the full list of 726 stocks from our Fast Growing Global Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Ningbo Sanxing Medical ElectricLtd (SHSE:601567)

Simply Wall St Growth Rating: ★★★★★★

Overview: Ningbo Sanxing Medical Electric Co., Ltd. manufactures and sells power distribution products in China and internationally, with a market cap of CN¥19.83 billion.

Operations: The company's revenue segments consist of CN¥2.98 billion from Medical Service and CN¥10.76 billion from Smart Power Distribution.

Insider Ownership: 24.9%

Earnings Growth Forecast: 56.8% p.a.

Ningbo Sanxing Medical Electric Ltd. demonstrates strong growth potential, with revenue expected to grow 26.8% annually, outpacing the Chinese market. Earnings are projected to rise significantly at 56.84% per year. Despite recent declines in profit margins and net income, the stock trades at a good relative value and below its estimated fair value by 68.7%. Analysts anticipate a price increase of 150.1%, although insider trading activity remains minimal recently.

• Click here to discover the nuances of Ningbo Sanxing Medical ElectricLtd with our detailed analytical future growth report.
• Our expertly prepared valuation report Ningbo Sanxing Medical ElectricLtd implies its share price may be lower than expected.

Meiko Electronics (TSE:6787)

Simply Wall St Growth Rating: ★★★★★★

Overview: Meiko Electronics Co., Ltd. designs, manufactures, and sells printed circuit boards and other electronic products across Japan, China, Vietnam, the rest of Asia, the United States, Europe, and internationally with a market cap of ¥504.86 billion.

Operations: The company generates revenue primarily from its Electronics-Related Business, which accounts for ¥260.60 billion.

Insider Ownership: 19.2%

Earnings Growth Forecast: 33.8% p.a.

Meiko Electronics is poised for robust growth, with revenue expected to increase by 23% annually, surpassing the Japanese market. Earnings are projected to grow significantly at 33.78% per year. Despite having a volatile share price recently and debt not well covered by operating cash flow, the company forecasts substantial profits with JPY 320 billion in net sales for FY2027. Insider trading activity has been minimal over the past three months.

• Navigate through the intricacies of Meiko Electronics with our comprehensive analyst estimates report here.
• Our valuation report here indicates Meiko Electronics may be overvalued.

Heron Neutron Medical (TWSE:7799)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Heron Neutron Medical Corp. develops, manufactures, and sells medical instruments with a market cap of NT$66.04 billion.

Operations: The company's revenue is primarily derived from its Medical Products segment, totaling NT$11.69 billion.

Insider Ownership: 12.2%

Earnings Growth Forecast: 170.3% p.a.

Heron Neutron Medical's revenue is forecast to grow rapidly at 70.3% annually, outpacing the Taiwanese market, despite current sales being below US$1 million. Earnings are expected to rise significantly by 170.34% per year, with profitability anticipated in three years, surpassing average market growth. However, recent financials show a net loss of TWD 107.42 million for Q2 2026 and a volatile share price over the past three months. No significant insider trading activity was reported recently.

• Get an in-depth perspective on Heron Neutron Medical's performance by reading our analyst estimates report here.
• The valuation report we've compiled suggests that Heron Neutron Medical's current price could be inflated.

Summing It All Up

• Navigate through the entire inventory of 726 Fast Growing Global Companies With High Insider Ownership here.
• Seeking Other Investments? AI is about to change healthcare. These 130 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com